logo
Plus   Neg
Share
Email

Amgen, Adaptive Partner To Find Neutralizing Antibodies For COVID-19

Amgen (AMGN) and Adaptive Biotechnologies (ADPT) announced they will collaborate to discover and develop fully human neutralizing antibodies targeting SARS-CoV-2 to potentially prevent or treat COVID-19. The companies will begin work immediately and finalize financial terms in the coming weeks.

Adaptive Biotechnologies will extend its high throughput platform to screen the genetic diversity of the B cell receptors from individuals that have recovered from COVID-19. This enables the identification of antibodies from survivors of COVID-19 to select those that neutralize SARS-CoV-2.

For comments and feedback contact: editorial@rttnews.com

Business News

Editors Pick
Tyson Foods, Inc. (TSN) reported third quarter adjusted net income per share attributable to company of $1.40 compared to $1.47, a year ago. On average, 12 analysts polled by Thomson Reuters expected the company to report profit per share of $0.94, for the quarter. Analysts' estimates typically exclude... Tailored Brands Inc., which owns menswear brands Men's Wearhouse and Jos. A. Bank, has filed for bankruptcy protection, severely hit by sluggish demand amid the coronavirus woes. The company filed for chapter 11 protection in the U.S. Bankruptcy Court for the Southern District of Texas to implement financial restructuring plan. Shares of HSBC Holdings Plc (HSBC, HSBA.L) were down in London and Hong Kong trading after the Asia-focused British lender reported Monday sharply lower profit in its second quarter, hurt by higher expected credit losses, weak revenues as well as the absence of prior year gain. For fiscal 2020, the company projects expected credit losses or ECL charge in the range of $8 billion to $13 billion.
Follow RTT